Breaking News
Get 40% Off 0
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One Click Copy for Free
Close

Cyclacel Pharmaceuticals Inc (CYCC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cyclacel's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.3100 -0.0100    -0.43%
09/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.4000
+0.0900
+3.8961%
23:29:44 - Real-time Data
  • Volume: 204,218
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.2711 - 2.6000
Type:  Equity
Market:  United States
Cyclacel 2.3100 -0.0100 -0.43%

Cyclacel Company Profile

 
Read the Cyclacel company profile to learn more about the business and the management team. View Cyclacel Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

12

Equity Type

ORD

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Contact Information

Address 200 Connell Drive Suite 1500
Berkeley Heights, 07922
United States
Phone 908 517 7330
Fax 866 271 3466

Top Executives

Name Age Since Title
Spiro George Rombotis 62 1997 President, CEO & Executive Director
Christopher S. Henney 80 2006 Independent Chairman
Robert Jay Spiegel 72 2018 Independent Vice Chairman
Paul McBarron 61 2006 Executive VP of Finance, CFO, COO, Secretary & Executive Director
Kenneth M. Ferguson 67 2022 Independent Director
Kenneth R. Harrap - - Member of Scientific Advisory Board
Michel E. Marty - - Member of Scientific Advisory Board
Edward Karol Sikora 74 - Member of Scientific Advisory Board
Stanley B. Kaye - - Member of Scientific Advisory Board
Samuel L. Barker 81 2014 Independent Director
Karin L. Walker 61 2020 Independent Director
Brian Schwartz 62 2020 Interim Chief Medical Officer & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CYCC Price Commentary

Write your thoughts about Cyclacel Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email